Kantipur Pharmaceuticals Lab Limited Appoints Muktinath Capital as Sales and Issue Manager for IPO

Kantipur Pharmaceuticals Lab Limited plans to issue an Initial Public Offering (IPO) of ordinary shares to the public, with Muktinath Capital managing the process.

The company will offer 11,00,000 shares, representing 14.86% of the total shares, to the general public.

The agreement was signed by Mr. Nawaraj Paudyal of Kantipur Pharmaceuticals and Mr. Kabindra Dhoj Joshi of Muktinath Capital at an event in Lalitpur.

Established in 2018, Kantipur Pharmaceuticals manufactures and distributes drugs and dietary supplements, complying with GMP and FAMI QS standards.

The company aims to expand its sales in Nepal and internationally, and the IPO marks the first such initiative in the veterinary medicine industry.